These studies help demonstrate that BRCA1 hypermethylation may prove as a minimally invasive approach for predicting patient response to standard therapies, especially since it has been found within ovarian cancer patient serum [53]. This evidence concerns the gene BRCA1 and ovarian carcinoma.